Your browser doesn't support javascript.
Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds.
Tzou, Philip L; Tao, Kaiming; Nouhin, Janin; Rhee, Soo-Yon; Hu, Benjamin D; Pai, Shruti; Parkin, Neil; Shafer, Robert W.
  • Tzou PL; Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Tao K; Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Nouhin J; Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Rhee SY; Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Hu BD; Undergraduate School of Humanities and Sciences, Stanford University, Stanford, CA 94305, USA.
  • Pai S; Undergraduate Studies, University of California, Berkeley, CA 94720, USA.
  • Parkin N; Data First Consulting Inc., Sebastopol, CA 95472, USA.
  • Shafer RW; Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA 94305, USA.
Viruses ; 12(9)2020 09 09.
Article in English | MEDLINE | ID: covidwho-760953
ABSTRACT

BACKGROUND:

To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy.

METHODS:

We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus compounds and placed extracted data in an online relational database.

RESULTS:

As of August 2020, the Coronavirus Antiviral Research Database (CoV-RDB; covdb.stanford.edu) contained over 2800 cell culture, entry assay, and biochemical experiments, 259 animal model studies, and 73 clinical studies from over 400 published papers. SARS-CoV-2, SARS-CoV, and MERS-CoV account for 85% of the data. Approximately 75% of experiments involved compounds with known or likely mechanisms of action, including monoclonal antibodies and receptor binding inhibitors (21%), viral protease inhibitors (17%), miscellaneous host-acting inhibitors (10%), polymerase inhibitors (9%), interferons (7%), fusion inhibitors (5%), and host protease inhibitors (5%). Of 975 compounds with known or likely mechanism, 135 (14%) are licensed in the U.S. for other indications, 197 (20%) are licensed outside the U.S. or are in human trials, and 595 (61%) are pre-clinical investigational compounds.

CONCLUSION:

CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Databases, Factual / Coronavirus Infections / Betacoronavirus Type of study: Prognostic study / Randomized controlled trials Topics: Traditional medicine Limits: Animals / Humans Language: English Year: 2020 Document Type: Article Affiliation country: V12091006

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Databases, Factual / Coronavirus Infections / Betacoronavirus Type of study: Prognostic study / Randomized controlled trials Topics: Traditional medicine Limits: Animals / Humans Language: English Year: 2020 Document Type: Article Affiliation country: V12091006